PGV-20229

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NamePGV-20229
Drug Alias Namedihydrobenzofuran analogs (Procter and Gamble)PG-229PGV-20229
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenase-2 inhibitorsArachidonate 5-lipoxygenase inhibitors
TargetsCyclooxygenase-2Arachidonate 5-lipoxygenase
Therapy Area/IndicationsPainInflammationArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesProcter & Gamble Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesProcter & Gamble Company
Active IndicationsN/A
Inactive IndicationsPainInflammationArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A